Pembrolizumab for previously treated endometrial cancer [ID1205]
Discontinued
Reference number: GID-TA10243
Following on from information provided to NICE by the company in February 2021, the appraisal of Pembrolizumab for previously treated endometrial cancer [ID1205] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.